Organization
Hospital Universitario Fundacion Favaloro, Buenos Aires, Argentina
1 abstract
Abstract
Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Expanded efficacy analysis from CheckMate 8HW.Org: Bristol Myers Squibb, Cancer Research SA, Fondazione Policlinico Universitario A. Gemelli IRCCS, Institut Paoli-Calmettes, Marseille, France, Instituto Catalán de Oncología,